EAS Newsletter March 21, 2023

EAS Education:

Webinar “Update on the impact of nutrition on ASCVD”, March 30

It’s time to announce the programme of the webinar.

17.00 CET Introduction to the Clinical case discussion, Philippe Moulin

17.05 CET SAF, not all so bad? Pr Jean Michel Lecerf Associate Professor Institut Pasteur Lille France,

17.20 CET Insights from Predimed: 10 years later. By Prof Ramon Estruch, Internal Medicine Department of the Hospital Clinic and Associate Professor at the Barcelona University Barcelona 

17.35 CET Q&A

To the webinar “Update on the impact of nutrition on ASCVD” registration

EAS Congress:

Late Breaking Abstract Submission

The late-breaking abstract submission for the 91st EAS Congress is still open. If you have new and groundbreaking research that was not available by the regular submission deadline, this is your chance to share it with the world. Please don´t hesitate to present your latest findings to the top experts in the field and submit your abstract now. The deadline is March 29, 2023.

To Late-Breaking Abstract Submission

EAS Education:

The 2nd Lp(a) Awareness Day

This week, there’s a new Lp(a) Awareness Day in our calendar, and activities planned to raise public awareness of Lp(a) as a risk factor for cardiovascular disease.

On Thursday, March 23rd, 17-18:00 CET, our partners FH Europe will host a free webinar, Beat the Odds of an Early Heart Attack: How to communicate Lp(a) risks to your doctor effectively, where Lp(a) patients themselves will share their experiences, together with Prof Florian Kronenberg.

To the webinar registration

EAS first published a Consensus statement on Lp(a) more than a decade ago. With the interest in Lp(a) increasing, Prof Kronenberg, with Prof Erik Stroes and Prof Samia Mora, chaired together a new EAS Consensus Panel and wrote an updated EAS Consensus paper on Lp(a), published last August.

This 2022 statement brings together extensive evidence for elevated Lp(a) concentration as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), irrespective of gender and ethnicity, as well as for aortic valve stenosis, and provides practical guidance on testing and treating high Lp(a) levels.

More information about the paper

For those looking to understand better the implications of the paper’s conclusions for clinical practice, visit the EAS Academy and our series of Lp(a) webinars – looking at what Lp(a) is, how to measure it, recommendations for screening, therapeutic approaches, and what all this means in practice.

To EAS Academy and our series of Lp(a) webinars

EAS Education:

EAS Lipotoxicity Course

The EAS LIPOTOXICITY COURSE aims to summarize and discuss our knowledge and perspectives on

the effect of lipid species on cell and organ function
the impact of lipotoxicity on organ damage
the contribution of metabolomics/lipidomics technologies toward better understanding of lipid metabolism, pathogenic mechanisms as well as identification of biomarkers and therapeutic target.

The event will be held in Prague, between June 8-9 2023. All information about the event and registration page you will find clicking on the button below:

To EAS Lipotoxicity Course

EAS Education: